Newcells Biotech builds in vitro models and services to de-risk and improve clinical translation and drug discovery
6 Liberty Square, Boston, MA 02109, United States
Founded in 2015 as a spin-out from Newcastle University
Worldwide collaborations with pharmas, biotechs & academic centres of excellence
State-of-the-art facilities in the heart of a science campus
Dr Mike Nicholds, CEO, talks about the drive behind the company and the mission to improve clinical translation using organoid models
Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. With a range of organoid models available, including retina models, kidney models and lung models, we enable the generation of robust and informative data and human organoids to support critical decisions during any stage of drug development in North America.
What drives us We believe that improving the in vitro models available to drug discovery and development scientists is a key method for increasing the efficiency of in-vitro to in-vivo translation. At Newcells Biotech, we produce organoid models designed to deliver new therapies to patients. Whether you are looking to offer these new stem cell therapies to patients or are seeking to improve your drug discovery and organoid research project, Newcells Biotech offer several predictive models to be used in our services or to be purchased as a product. By applying our expertise in induced pluripotent stem cells (iPSCs), primary tissues, cellular physiology and organoid technology, we have built validated models and assays that have proven to be predictive of how drugs interact with tissues and organs. We operate across North America, providing support with organoid research, the application of organoids and overall organoid models.
View our in vitro tissue models for drug discoveryFounders
Executive Team
Non-Executive Board
Non-Executive Director
Our services and products help our clients get the data they need
Combining expert know-how and extensive capabilities, our services and & products generate predictive human in vitro data. At Newcells Biotech, our approach is based on validated organoid models, which enables a deeper understanding of how new drugs interact with specific tissues and provide key mechanistic insights relating to the safety and efficacy of new therapeutic compounds.
Derived from stem cells, our organoid models, or 3D organoids, are developed using organoid culture. These organoid models are:
- Characterised and tested to mimic the phenotype of the in vivo tissue
- Validated assays conducted under quality control to give data confidence
- Available in human and animal cell versions which enables cross-species comparison
- Proven to provide predictive data on behaviour in vivo
- Adapted to medium throughput high content screening
- Proven in hundreds 100’s of customer studies on efficacy, safety and drug transport
Newcells Biotech’s organoid models produce data you can rely on.
We are the leading provider of in vitro tissue organoid models of the kidney, retina and lung in North America.
Contact us
Our Investors
Newcells is funded by the founders, venture and private equity investors
